Summary
This phase 3 randomised controlled trial evaluated ramucirumab, a VEGF receptor-2 antagonist, combined with docetaxel against placebo plus docetaxel as second-line therapy for patients with locally advanced or metastatic urothelial carcinoma refractory to platinum-based chemotherapy. The multicentre international study measured survival and safety outcomes to inform treatment options for this advanced cancer population. Published in The Lancet in 2017, the trial contributes evidence on targeted combination therapy efficacy in post-platinum urothelial cancer.
UK applicability
Findings from this international phase 3 trial are directly applicable to UK oncology practice, informing treatment decisions for eligible patients with platinum-refractory urothelial carcinoma within NHS cancer centres. UK participation in the trial and alignment with international standards suggest relevance to current National Institute for Health and Care Excellence (NICE) appraisal of second-line therapies.
Key measures
Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse events
Outcomes reported
The study measured overall survival, progression-free survival, and safety outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with ramucirumab plus docetaxel versus placebo plus docetaxel.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.